Fibroblast Growth Factor 21 Prevents Atherosclerosis by Suppression of Hepatic Sterol Regulatory Element-Binding Protein-2 and Induction of Adiponectin in Mice. Issue 21 (26th May 2015)
- Record Type:
- Journal Article
- Title:
- Fibroblast Growth Factor 21 Prevents Atherosclerosis by Suppression of Hepatic Sterol Regulatory Element-Binding Protein-2 and Induction of Adiponectin in Mice. Issue 21 (26th May 2015)
- Main Title:
- Fibroblast Growth Factor 21 Prevents Atherosclerosis by Suppression of Hepatic Sterol Regulatory Element-Binding Protein-2 and Induction of Adiponectin in Mice
- Authors:
- Lin, Zhuofeng
Pan, Xuebo
Wu, Fan
Ye, Dewei
Zhang, Yi
Wang, Yu
Jin, Leigang
Lian, Qizhou
Huang, Yu
Ding, Hong
Triggle, Chris
Wang, Kai
Li, Xiaokun
Xu, Aimin - Abstract:
- <abstract> <title> <x xml:space="preserve">Abstract</x> </title> <sec> <title>Background—</title> <p>Fibroblast growth factor 21 (FGF21) is a metabolic hormone with pleiotropic effects on glucose and lipid metabolism and insulin sensitivity. It acts as a key downstream target of both peroxisome proliferator-activated receptor α and γ, the agonists of which have been used for lipid lowering and insulin sensitization, respectively. However, the role of FGF21 in the cardiovascular system remains elusive.</p> </sec> <sec> <title>Methods and Results—</title> <p>The roles of FGF21 in atherosclerosis were investigated by evaluating the impact of FGF21 deficiency and replenishment with recombinant FGF21 in apolipoprotein E<sup>−/−</sup> mice. FGF21 deficiency causes a marked exacerbation of atherosclerotic plaque formation and premature death in apolipoprotein E<sup>−/−</sup> mice, which is accompanied by hypoadiponectinemia and severe hypercholesterolemia. Replenishment of FGF21 protects against atherosclerosis in apolipoprotein E<sup>−/−</sup>mice via 2 independent mechanisms, inducing the adipocyte production of adiponectin, which in turn acts on the blood vessels to inhibit neointima formation and macrophage inflammation, and suppressing the hepatic expression of the transcription factor sterol regulatory element-binding protein-2, thereby leading to reduced cholesterol synthesis and attenuation of hypercholesterolemia. Chronic treatment with adiponectin partially reverses<abstract> <title> <x xml:space="preserve">Abstract</x> </title> <sec> <title>Background—</title> <p>Fibroblast growth factor 21 (FGF21) is a metabolic hormone with pleiotropic effects on glucose and lipid metabolism and insulin sensitivity. It acts as a key downstream target of both peroxisome proliferator-activated receptor α and γ, the agonists of which have been used for lipid lowering and insulin sensitization, respectively. However, the role of FGF21 in the cardiovascular system remains elusive.</p> </sec> <sec> <title>Methods and Results—</title> <p>The roles of FGF21 in atherosclerosis were investigated by evaluating the impact of FGF21 deficiency and replenishment with recombinant FGF21 in apolipoprotein E<sup>−/−</sup> mice. FGF21 deficiency causes a marked exacerbation of atherosclerotic plaque formation and premature death in apolipoprotein E<sup>−/−</sup> mice, which is accompanied by hypoadiponectinemia and severe hypercholesterolemia. Replenishment of FGF21 protects against atherosclerosis in apolipoprotein E<sup>−/−</sup>mice via 2 independent mechanisms, inducing the adipocyte production of adiponectin, which in turn acts on the blood vessels to inhibit neointima formation and macrophage inflammation, and suppressing the hepatic expression of the transcription factor sterol regulatory element-binding protein-2, thereby leading to reduced cholesterol synthesis and attenuation of hypercholesterolemia. Chronic treatment with adiponectin partially reverses atherosclerosis without obvious effects on hypercholesterolemia in FGF21-deficient apolipoprotein E<sup>−/−</sup> mice. By contrast, the cholesterol-lowering effects of FGF21 are abrogated by hepatic expression of sterol regulatory element-binding protein-2.</p> </sec> <sec> <title>Conclusions—</title> <p>FGF21 protects against atherosclerosis via fine tuning the multiorgan crosstalk among liver, adipose tissue, and blood vessels.</p> </sec> </abstract> … (more)
- Is Part Of:
- Circulation. Volume 131:Issue 21(2015)
- Journal:
- Circulation
- Issue:
- Volume 131:Issue 21(2015)
- Issue Display:
- Volume 131, Issue 21 (2015)
- Year:
- 2015
- Volume:
- 131
- Issue:
- 21
- Issue Sort Value:
- 2015-0131-0021-0000
- Page Start:
- Page End:
- Publication Date:
- 2015-05-26
- Subjects:
- Blood -- Circulation -- Periodicals
Cardiovascular system -- Periodicals
Cardiology -- Periodicals
Heart -- Diseases -- Periodicals
Blood Circulation
Cardiovascular System
Vascular Diseases
616.1 - Journal URLs:
- http://ovidsp.tx.ovid.com/sp-3.4.2a/ovidweb.cgi?&S=HFFJFPCLPODDKOLGNCALDCMCIACKAA00&Browse=Toc+Children%7cNO%7cS.sh.1384_1326796138_84.1384_1326796138_96.1384_1326796138_97%7c66%7c50 ↗
http://www.circulationaha.org ↗
http://circ.ahajournals.org/ ↗
http://journals.lww.com ↗ - DOI:
- 10.1161/CIRCULATIONAHA.115.015308 ↗
- Languages:
- English
- ISSNs:
- 0009-7322
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3265.200000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 3017.xml